Susquehanna International Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Susquehanna International Group’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.88M	Buy	+108,500	New	+$1.49M	﹤0.01%	6622
2026 Q1	–	Sell	-216,800	Closed	-$2.73M	–	13103
2025 Q4	$2.73M	Sell	216,800 -85,200	-28%	-$975K	﹤0.01%	5048
2025 Q3	$3.02M	Buy	302,000 +210,900	+232%	+$1.89M	﹤0.01%	4964
2025 Q2	$737K	Sell	91,100 -66,500	-42%	-$501K	﹤0.01%	8218
2025 Q1	$1.32M	Buy	157,600 +46,200	+41%	+$386K	﹤0.01%	6546
2024 Q4	$882K	Buy	111,400 +63,800	+134%	+$535K	﹤0.01%	7279
2024 Q3	$396K	Sell	47,600 -26,200	-36%	-$205K	﹤0.01%	9012
2024 Q2	$469K	Sell	73,800 -55,800	-43%	-$354K	﹤0.01%	8421
2024 Q1	$785K	Sell	129,600 -19,600	-13%	-$111K	﹤0.01%	7448
2023 Q4	$906K	Buy	149,200 +56,200	+60%	+$250K	﹤0.01%	7224
2023 Q3	$392K	Sell	93,000 -600	-0.6%	-$2.24K	﹤0.01%	8788
2023 Q2	$290K	Buy	93,600 +73,200	+359%	+$156K	﹤0.01%	9513
2023 Q1	$28.4K	Sell	20,400 -5,900	-22%	-$11.7K	﹤0.01%	11935
2022 Q4	$52.3K	Sell	26,300 -99,300	-79%	-$223K	﹤0.01%	11370
2022 Q3	$254K	Buy	125,600 +40,600	+48%	+$114K	﹤0.01%	10232
2022 Q2	$270K	Sell	85,000 -29,300	-26%	-$106K	﹤0.01%	9845
2022 Q1	$477K	Sell	114,300 -76,800	-40%	-$340K	﹤0.01%	9114
2021 Q4	$915K	Sell	191,100 -139,000	-42%	-$693K	﹤0.01%	7542
2021 Q3	$1.76M	Buy	330,100 +78,900	+31%	+$397K	﹤0.01%	6114
2021 Q2	$1.29M	Sell	251,200 -31,600	-11%	-$180K	﹤0.01%	7053
2021 Q1	$1.9M	Buy	282,800 +16,800	+6%	+$93.1K	﹤0.01%	6046
2020 Q4	$1.22M	Sell	266,000 -40,500	-13%	-$179K	﹤0.01%	6248
2020 Q3	$1.19M	Sell	306,500 -13,600	-4%	-$58.2K	﹤0.01%	5700
2020 Q2	$1.52M	Buy	320,100 +287,300	+876%	+$1.18M	﹤0.01%	5002
2020 Q1	$114K	Buy	+32,800	New	+$139K	﹤0.01%	9226
2019 Q3	–	Sell	-38,100	Closed	-$273K	–	10109
2019 Q2	$273K	Buy	38,100 +27,500	+259%	+$281K	﹤0.01%	8504
2019 Q1	$150K	Sell	10,600 -26,800	-72%	-$354K	﹤0.01%	8049
2018 Q4	$506K	Buy	+37,400	New	+$674K	﹤0.01%	6007

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Susquehanna International Group's AMRX Position: Q2 2026 in Review

Susquehanna International Group reduced its Amneal Pharmaceuticals (AMRX) stake by 59% in Q2 2026, selling an estimated $422K and leaving 21,774 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #10554.

Susquehanna International Group first reported a position in AMRX in Q2 2018 and has held it in 30 quarters since. The position peaked at $16.7M in Q4 2025. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Susquehanna International Group held 21,774 shares of Amneal Pharmaceuticals worth $377K as of Q2 2026.
Susquehanna International Group sold 30,769 Amneal Pharmaceuticals shares in Q2 2026, an estimated $422K.
Amneal Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #10554 holding.
Susquehanna International Group first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
Susquehanna International Group's Amneal Pharmaceuticals position peaked at $16.7M in Q4 2025.
311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.